Kezar Life Sciences Inc.(KZR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KZR Kezar Life Sciences Inc.

交易中 11-21 14:40:42 EST

7.54

+0.05

+0.60%

最高7.63	最低7.47	成交量2.40万
今开7.50	昨收7.49	日振幅2.14%
总市值5,498万	流通市值3,424万	总股本729.62万
成交额18.09万	换手率0.53%	流通股本454.41万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"KZR","market":"US","secType":"STK","nameCN":"Kezar Life Sciences Inc.","latestPrice":7.535,"timestamp":1732218024919,"preClose":7.49,"halted":0,"volume":23975,"delay":0,"floatShares":4544057,"shares":7296222,"eps":-13.54562,"marketStatus":"交易中","marketStatusCode":2,"change":0.045,"latestTime":"11-21 14:40:42 EST","open":7.5,"high":7.63,"low":7.47,"amount":180948.4235125,"amplitude":0.021362,"askPrice":7.59,"askSize":200,"bidPrice":7.49,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-13.54562,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732222800000},"adr":0,"listingDate":1529553600000,"adjPreClose":7.49,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":7.42,"preClose":7.49,"latestTime":"08:55 EST","volume":1,"amount":7.42,"timestamp":1732197357599},"postHourTrading":{"tag":"盘后","latestPrice":7.69,"preClose":7.49,"latestTime":"19:57 EST","volume":558,"amount":4275.626,"timestamp":1732150658161},"volumeRatio":0.472713,"impliedVol":1.8231,"impliedVolPercentile":0.9522},"requestUrl":"/m/hq/s/KZR","defaultTab":"news","newsList":[{"id":"2484391651","title":"Kezar Life Sciences, Inc.2024财年第三财季实现净利润-20.31百万美元，同比增加12.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484391651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484391651?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010422,"startTime":"0","endTime":"0","summary":"11月19日，Kezar Life Sciences, Inc.公布财报，公告显示公司2024财年第三财季净利润为-20.31百万美元，同比增加12.08%；其中营业收入为0.00美元，每股基本收益为-2.78美元。机构评级：截至2024年11月19日，当前有2家机构对Kezar Life Sciences, Inc.目标价做出预测，其中目标均价为14.50美元，其中最低目标价为11.00美元，最高目标价为18.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180048abcedf0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180048abcedf0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR"],"gpt_icon":0},{"id":"2483886793","title":"Kezar 生命科学公司公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886793","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483886793?lang=zh_cn&edition=full","pubTime":"2024-11-13 22:20","pubTimestamp":1731507650,"startTime":"0","endTime":"0","summary":"Kezar 生命科学公司公布截至 9 月 30 日的季度业绩 - 收益摘要Kezar Life Sciences Inc KZR.OQ报告，截至9月30日的季度调整后每股亏损2.78美元，高于去年同期的每股收益3.20美元。六位分析师对该季度的平均预期是每股亏损 3.15 美元。华尔街预期为每股亏损 3.80 美元至 2.30 美元。该公司季度亏损 2,031 万美元。Kezar Life Sciences Inc 的股价本季度下跌了 3.1%，今年迄今为止下跌了 20.9%。华尔街对 Kezar 生命科学公司 12 个月目标价的中位数为 19.00 本摘要由 LSEG 11 月 13 日 02:20 p.m. UTC 调制解调器器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4T3MK1D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR"],"gpt_icon":0},{"id":"2482736015","title":"Kezar Life Sciences Inc  预计每股亏损 3.15 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2482736015","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482736015?lang=zh_cn&edition=full","pubTime":"2024-11-11 23:33","pubTimestamp":1731339199,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences Inc  预计每股亏损 3.15 美元 - 财报前瞻Kezar Life Sciences Inc KZR.OQ KZR.O预计将在11月13日公布截至0001年1月1日的业绩报告(估计)，季度收入将出现下降。根据 LSEG 的数据，5 位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山南部的公司的营收预计将从去年同期的 700 万美元下降 88.6%，至 80 万美元。LSEG 分析师对 Kezar 生命科学公司的平均预期是每股亏损 3.15 美元。华尔街对 Kezar Life Sciences Inc 的 12 个月目标价中位数为 25.00 美元，高于其最新收盘价 7.37 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL4S3MI13W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR"],"gpt_icon":0},{"id":"2479708006","title":"Kezar Life Sciences, Inc.盘中异动 大幅下跌9.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479708006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479708006?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:32","pubTimestamp":1730381563,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日21时32分，Kezar Life Sciences, Inc.股票出现波动，股价急速跳水9.89%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为1.85%。其相关个股中，Aerovate Therapeutics, Inc.、Engene Holdings Inc C/Wts 31/10/2028  Cl A、180 Life Sciences Corp C/Wts 07/11/2025涨幅较大，Evogene Ltd.、Aditxt, Inc.、Palisade Bio, Inc.较为活跃，换手率分别为192.44%、186.36%、145.93%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Equillium, Inc.、Aerovate Therapeutics, Inc.，振幅分别为21.98%、14.49%、9.59%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121324395bd9c2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121324395bd9c2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2479478376","title":"Kezar Life Sciences, Inc.盘中异动 股价大跌5.12%报7.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479478376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479478376?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:31","pubTimestamp":1730295080,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时31分，Kezar Life Sciences, Inc.股票出现波动，股价急速下跌5.12%。截至发稿，该股报7.12美元/股，成交量7791股，换手率0.11%，振幅0.00%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，Tharimmune, Inc.、Ensysce Biosciences, Inc.、Tiziana Life Sciences Ltd涨幅较大，Tharimmune, Inc.、Ensysce Biosciences, Inc.、Gri Bio, Inc.较为活跃，换手率分别为1673.30%、97.73%、13.89%，振幅较大的相关个股有Tharimmune, Inc.、Cormedix Inc.、Dogwood Therapeutics, Inc.，振幅分别为20.69%、8.86%、6.95%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213124971a33a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213124971a33a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KZR"],"gpt_icon":0},{"id":"2479289161","title":"Kezar Life Sciences, Inc.盘中异动 早盘股价大跌5.49%报0.730美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479289161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479289161?lang=zh_cn&edition=full","pubTime":"2024-10-29 22:13","pubTimestamp":1730211230,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日22时13分，Kezar Life Sciences, Inc.股票出现波动，股价快速下跌5.49%。截至发稿，该股报0.730美元/股，成交量20.0846万股，换手率0.28%，振幅5.63%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029221350971a2f42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029221350971a2f42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2477860612","title":"Kezar Life Sciences, Inc.盘中异动 临近午盘股价大跌5.04%报0.782美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477860612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477860612?lang=zh_cn&edition=full","pubTime":"2024-10-21 23:36","pubTimestamp":1729524989,"startTime":"0","endTime":"0","summary":"北京时间2024年10月21日23时36分，Kezar Life Sciences, Inc.股票出现异动，股价快速跳水5.04%。截至发稿，该股报0.782美元/股，成交量7.5158万股，换手率0.10%，振幅4.54%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为1.09%。其相关个股中，Genprex, Inc.、Gri Bio, Inc.、Biovie Inc.涨幅较大，Genprex, Inc.、Gri Bio, Inc.、Biovie Inc.较为活跃，换手率分别为6393.24%、3062.65%、1353.30%，振幅较大的相关个股有Genprex, Inc.、Biovie Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为369.73%、157.02%、148.15%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102123363098e3d932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102123363098e3d932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KZR"],"gpt_icon":0},{"id":"2476061691","title":"BUZZ--美国股票走势-艾利丹尼森、Snap-On、Avadel Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2476061691","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476061691?lang=zh_cn&edition=full","pubTime":"2024-10-18 00:01","pubTimestamp":1729180889,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      10月17日 - 华尔街周四上涨，标普500指数和道琼斯指数盘中触及纪录高位，受台积电乐观预期和月度零售销售超预期增长推动，表明美国消费者强劲。美东时间11:32，道琼斯工业平均指数  上涨0.4%，报43,238.32点。标普500指数  上涨0.29%，报5859.7点；纳斯达克综合指数  上涨0.36%，报18432.436点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSX","GRTS","STLD","CAPR","L","WING",".IXIC",".SPX","SAGE","SHAK","XRX","AVDL","CLMT","TMO","SBUX","UDOW","CBSH","AVY","PIXY","EFX","WAT","WATT",".DJI","SLQT","ZUO","DFS","LCID","MNQmain","VSCO","DDM","PSQ","SNA","MBIN","ULTA","SDOW","GWW","KZR"],"gpt_icon":1},{"id":"2476212705","title":"BUZZ-Kezar 生命科学公司因终止狼疮药物中期试验而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2476212705","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476212705?lang=zh_cn&edition=full","pubTime":"2024-10-17 21:34","pubTimestamp":1729172058,"startTime":"0","endTime":"0","summary":"    10月17日 - ** 药物开发商Kezar Life Sciences   早盘股价下跌近9%至0.81美元** Kezar表示， ，它将停止对活动性狼疮肾炎患者进行实验性药物的中期试验** 表示将集中资源开发治疗自身免疫性肝炎的药物zetomipzomib** 本月早些时候，美国食品和药物管理局对该药物治疗狼疮的临床试验暂停 。** 另外，该公司还拒绝了  Concentra Biosciences 公司提出的每股 1.10 美元外加或有价值权的收购建议，称 \"该交易大大低估了公司的价值\"。** 截至上次收盘，股价年累计下跌 5.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR"],"gpt_icon":0},{"id":"2476112717","title":"Kezar Life Sciences, Inc.盘中异动 大幅跳水5.00%报0.850美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476112717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476112717?lang=zh_cn&edition=full","pubTime":"2024-10-17 21:30","pubTimestamp":1729171857,"startTime":"0","endTime":"0","summary":"北京时间2024年10月17日21时30分，Kezar Life Sciences, Inc.股票出现波动，股价快速下跌5.00%。截至发稿，该股报0.850美元/股，成交量32.7704万股，换手率0.45%，振幅0.56%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101721305898e3cfd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101721305898e3cfd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KZR"],"gpt_icon":0},{"id":"2476170126","title":"Kezar终止狼疮治疗中期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2476170126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476170126?lang=zh_cn&edition=full","pubTime":"2024-10-17 20:46","pubTimestamp":1729169160,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透10月17日 - Kezar Life Sciences   周四表示，它将终止在活动性狼疮肾炎患者中研究实验性药物的中期试验，专注于开发治疗自身免疫性肝炎的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2474225801","title":"Kezar Life Sciences, Inc.股价拉升22.97% 市值涨1525.12万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474225801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474225801?lang=zh_cn&edition=full","pubTime":"2024-10-09 21:31","pubTimestamp":1728480661,"startTime":"0","endTime":"0","summary":"北京时间2024年10月09日21时31分，Kezar Life Sciences, Inc.股票出现异动，股价急速上涨22.97%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Psyence Biomedical Ltd C/Wts 25/01/2029、Inhibikase Therapeutics, Inc.、Kezar Life Sciences, Inc.涨幅较大，Windtree Therapeutics, Inc.、Aditxt, Inc.、Gri Bio, Inc.较为活跃，换手率分别为605.03%、68.34%、33.65%，振幅较大的相关个股有Cue Biopharma, Inc.、Inhibikase Therapeutics, Inc.、Calidi Biotherapeutics, Inc.，振幅分别为19.51%、10.92%、5.56%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009213101959af608&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009213101959af608&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","KZR","BK4139"],"gpt_icon":0},{"id":"2473106123","title":"Kezar Life Sciences, Inc.盘中异动 早盘快速下跌5.05%报0.757美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473106123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473106123?lang=zh_cn&edition=full","pubTime":"2024-10-07 21:58","pubTimestamp":1728309480,"startTime":"0","endTime":"0","summary":"北京时间2024年10月07日21时58分，Kezar Life Sciences, Inc.股票出现波动，股价急速下挫5.05%。截至发稿，该股报0.757美元/股，成交量10.3465万股，换手率0.14%，振幅2.47%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241007215800ab681b64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241007215800ab681b64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2473915952","title":"更新版 1-患者死亡后，美国 FDA 暂停了 Kezar 生命科学公司的狼疮治疗试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2473915952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473915952?lang=zh_cn&edition=full","pubTime":"2024-10-05 05:54","pubTimestamp":1728078896,"startTime":"0","endTime":"0","summary":"     路透10月4日 - 美国食品和药物管理局已暂停Kezar生命科学公司  治疗狼疮实验药物的临床试验，该公司周五表示。FDA作出这一决定之前，该公司曾表示，在菲律宾和阿根廷参与试验的四名患者死亡后，它已暂停了该药物的中期试验 ，以审查安全性数据。该公司表示，另一项在自身免疫性肝炎患者中测试zetomipzomib的中期试验仍在进行中，到目前为止还没有严重不良事件的报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR"],"gpt_icon":0},{"id":"2473918378","title":"美国 FDA 暂停 Kezar 生命科学公司狼疮治疗试验的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2473918378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473918378?lang=zh_cn&edition=full","pubTime":"2024-10-05 05:08","pubTimestamp":1728076104,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透10月4日 - 美国食品和药物管理局已暂停Kezar生命科学公司  治疗狼疮实验药物的临床试验，该公司周五表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2472682379","title":"Kezar Life Sciences, Inc.盘中异动 大幅跳水5.16%报0.783美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472682379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472682379?lang=zh_cn&edition=full","pubTime":"2024-10-04 22:28","pubTimestamp":1728052106,"startTime":"0","endTime":"0","summary":"北京时间2024年10月04日22时28分，Kezar Life Sciences, Inc.股票出现波动，股价快速下跌5.16%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Geovax Labs Inc C/Wts 29/09/2025、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Theriva Biologics, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为14098.31%、47.02%、34.95%，振幅较大的相关个股有Geovax Labs Inc C/Wts 29/09/2025、Aditxt, Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 ，振幅分别为58.64%、47.42%、38.39%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410042228269719e662&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410042228269719e662&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2472057313","title":"Kezar Life Sciences, Inc.盘中异动 临近午盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472057313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472057313?lang=zh_cn&edition=full","pubTime":"2024-10-02 23:52","pubTimestamp":1727884327,"startTime":"0","endTime":"0","summary":"北京时间2024年10月02日23时52分，Kezar Life Sciences, Inc.股票出现异动，股价快速拉升5.02%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为0.76%。其相关个股中，Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Tc Biopharm  Plc C/Wts 10/02/2028 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Aditxt, Inc.、Windtree Therapeutics, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为992.93%、51.75%、42.64%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Aditxt, Inc.、Briacell Therapeutics Corp C/Wts 24/02/2025，振幅分别为145.55%、51.53%、49.10%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410022352079719dfdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410022352079719dfdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2472303165","title":"Kezar Life Sciences, Inc.盘中异动 大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472303165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472303165?lang=zh_cn&edition=full","pubTime":"2024-10-01 23:30","pubTimestamp":1727796623,"startTime":"0","endTime":"0","summary":"北京时间2024年10月01日23时30分，Kezar Life Sciences, Inc.股票出现波动，股价快速拉升5.08%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Aditxt, Inc.、Silexion Therapeutics Corp、Sagimet Biosciences Inc. - Series A较为活跃，换手率分别为638.58%、563.67%、117.81%，振幅较大的相关个股有Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Tc Biopharm  Plc C/Wts 10/02/2028 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为97.67%、82.42%、64.35%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241001233023ab6753d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241001233023ab6753d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2471388032","title":"Kezar Life Sciences, Inc.盘中异动 急速上涨17.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2471388032","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471388032?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:32","pubTimestamp":1727703135,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日21时32分，Kezar Life Sciences, Inc.股票出现波动，股价急速拉升17.78%。Kezar Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Prime Medicine, Inc.涨幅较大，Aditxt, Inc.、Windtree Therapeutics, Inc.、Onconetix, Inc.较为活跃，换手率分别为31.07%、18.12%、14.79%，振幅较大的相关个股有Prime Medicine, Inc.、Vor Biopharma Inc.、Tharimmune, Inc.，振幅分别为16.76%、9.87%、9.80%。Kezar Life Sciences, Inc.公司简介：Kezar Life Sciences Inc 是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409302132159f215bdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409302132159f215bdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2471384681","title":"更新版 2-患者死亡后，Kezar 生命科学公司暂停狼疮治疗试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2471384681","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471384681?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:04","pubTimestamp":1727701453,"startTime":"0","endTime":"0","summary":"更新版 2-患者死亡后，Kezar 生命科学公司暂停狼疮治疗试验第2段增加了通知监管机构的细节，第6-8段增加了背景资料路透9月30日 - Kezar Life Sciences KZR.O周一表示，由于有四名患者在中期研究中死亡，该公司已暂停了一项治疗狼疮的实验性药物试验，以审查安全性数据。据Kezar公司称，迄今为止，已有84名患者加入了这项中期试验。该公司表示，在此前的zetomipzomib临床研究中未发现任何死亡或严重感染病例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nL4T3LC11Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kezarlifesciences.com","stockEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":-0.0547},{"period":"3month","weight":0.2253},{"period":"6month","weight":0.0624},{"period":"1year","weight":-0.1489},{"period":"ytd","weight":-0.2094}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kezar Life Sciences, Inc.于2015年2月19日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，发现并开发新型小分子疗法，用于治疗免疫介导疾病和癌症中未满足的需求。该公司正在推进两个药物开发计划，利用细胞功能的不同调节剂：第一个针对负责免疫系统细胞中蛋白质降解并驱动免疫细胞功能的许多关键方面的免疫蛋白酶体，第二个针对位于内质网上并代表蛋白质分泌途径开始的Sec61转座子。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.101182},{"month":2,"riseRate":0.833333,"avgChangeRate":0.110013},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.094959},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.079081},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.18188},{"month":6,"riseRate":0.333333,"avgChangeRate":0.038813},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.058216},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.003228},{"month":9,"riseRate":0.428571,"avgChangeRate":0.037638},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.061141},{"month":11,"riseRate":0.857143,"avgChangeRate":0.175297},{"month":12,"riseRate":0.5,"avgChangeRate":0.060617}],"exchange":"NASDAQ","name":"Kezar Life Sciences Inc.","nameEN":"Kezar Life Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kezar Life Sciences Inc.(KZR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kezar Life Sciences Inc.(KZR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kezar Life Sciences Inc.,KZR,Kezar Life Sciences Inc.股票,Kezar Life Sciences Inc.股票老虎,Kezar Life Sciences Inc.股票老虎国际,Kezar Life Sciences Inc.行情,Kezar Life Sciences Inc.股票行情,Kezar Life Sciences Inc.股价,Kezar Life Sciences Inc.股市,Kezar Life Sciences Inc.股票价格,Kezar Life Sciences Inc.股票交易,Kezar Life Sciences Inc.股票购买,Kezar Life Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kezar Life Sciences Inc.(KZR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kezar Life Sciences Inc.(KZR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}